MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: Detection of naturally acquired responses and identification of new epitopes

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 23-35

  Cesson, Valérie ^a   Rivals, Jean Paul ^a   Escher, Anette ^a   Piotet, Elsa ^a   Thielemans, Kris ^b   Posevitz, Vilmos ^a   Dojcinovic, Danijel ^c   Monnier, Philippe ^a   Speiser, Daniel ^a   Bron, Luc ^a   Romero, Pedro ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

CD4+ T cells; HNSCC; MAGE A3; MAGE A4

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HEAD AND NECK CARCINOMA; HLA TYPING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HEAD AND NECK NEOPLASMS; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 79953760144     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0916-z     Document Type: Article

References (38)

1. Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, De Leo AB (2005) p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol 62:151-160. doi:10.1159/000082505 (Pubitemid 40014313)
2. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191(4):625-630
3. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100(15):8862-8867. doi:10.1073/pnas.1133324100
4. McNeel DG, Nguyen LD, Disis ML (2001) Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 61(13):5161-5167 (Pubitemid 32681549)
5. Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P (2006) Melan-a/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 177(10):6769-6779 (Pubitemid 44715041)
6. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC (2007) Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in nonsmall cell lung cancer. Int J Cancer 120(2):337-343 (Pubitemid 44956843)
7. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of mage genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375-380
8. Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, Liénard D, Monnier P, Romero P, Bron L, Rimoldi D (2010) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer [Epub ahead of print]
9. Speiser DE, Romero P (2010) Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 22:144-154. doi:10.1016/j.smim.2010.03.004
10. + T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172(5):3289-3296
11. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187(8):1349-1354 (Pubitemid 28189124)
12. Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG (2006) Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 55(2):178-184 (Pubitemid 41682589)
13. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U (1997) A sensitive elispot assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3(2):221-226 (Pubitemid 27107298)
14. Dhodapkar MV, Young JW, Chapman PB, Cox WI, Fonteneau JF, Amigorena S, Houghton AN, Steinman RM, Bhardwaj N (2000) Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res 6(12):4831-4838 (Pubitemid 32110427)
15. Inokuma M, dela Rosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang M, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML, Maecker HT (2007) Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol 179(4):2627-2633
16. Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Gueguen M (2004) Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27(2):124-135 (Pubitemid 38282732)
17. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189(5):767-778
18. Guillaume P, Dojcinovic D, Luescher IF (2009) Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun 9:7
19. + helper T cell responses in cancer patients. Blood 106(3):1008-1011. doi:10.1182/blood-2005-02-0607
20. + T-cell epitopes on the tumor antigen MAGE-3. Blood 101(3):1038-1044. doi:10.1182/blood-2002-03-0933
21. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189(5):871-876 (Pubitemid 29189692)
22. Marturano J, Longhi R, Casorati G, Protti MP (2008) MAGEA3( 161-175) contains an HLA-DRBETA4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunol Immunother 57(2):207-215. doi:10.1007/s00262-007-0364-6 (Pubitemid 350159922)
23. + T cell clones in the naive polyclonal repertoire. Proc Natl Acad Sci USA 106(27):11241-11245. doi:10.1073/pnas.0902015106
24. Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H (2005) Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and sage. Clin Cancer Res 11(15):5581-5589. doi:10.1158/1078-0432.CCR-04-2585 (Pubitemid 41060836)
25. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169(1):575-580 (Pubitemid 34686181)
26. Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 29(10):3329-3337. doi:10.1002/(SICI)1521-4141(199910) 29:10〈3329:AID-IMMU3329〉3.0.CO;2-7 (Pubitemid 29484224)
27. Ohkuri T, Wakita D, Chamoto K, Togashi Y, Kitamura H, Nishimura T (2009) Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 100(7):1135-1143. doi:10.1038/sj.bjc.6604966
28. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59(1):1-14 (Pubitemid 28141258)
29. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51-64 (Pubitemid 35398865)
30. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61(12):4773-4778 (Pubitemid 32691890)
31. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71(6):932-936. doi:10.1002/(SICI)1097-0215(19970611)71:6〈932:AID- IJC3〉3.0.CO;2-Z (Pubitemid 27252870)
32. Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, Leng XS, Chen WF (2007) Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 56(12):1945-1954. doi:10.1007/s00262-007-0338-8 (Pubitemid 47512615)
33. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J (2008) Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 30(2):251-261. doi:10.1002/hed.20739
34. Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125(1):82-88 (Pubitemid 29074903)
35. Young MR (2006) Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28(5):462-470. doi:10.1002/hed.20331
36. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650-1655. doi:10.1073/pnas.0707140104 (Pubitemid 351346569)
37. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39(1):70-77 (Pubitemid 36005427)
38. Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D (2000) Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol 165(12):7253-7261 (Pubitemid 32001204)